Skip to content

Cencora

US · COR #374 by market cap Listed 1970
339.09 -2.16 -0.63%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:52

Official SEC filings

Source: SEC EDGAR. Latest available cached filings; filing date is not the financial period end. Index checked: 2026-11-22 01:43 UTC.

FormFiledOriginal document
8-K2026-11-04Read on SEC.gov
8-K2026-11-04Read on SEC.gov
8-K2026-10-21Read on SEC.gov
8-K2026-09-25Read on SEC.gov
8-K2026-08-14Read on SEC.gov
8-K2026-08-12Read on SEC.gov
10-Q2026-08-05Read on SEC.gov
8-K2026-08-05Read on SEC.gov

SEC annual financial snapshot

Standard US-GAAP facts in 10-K filings, USD. Income and cash flow cover the annual period; balance-sheet amounts are as of period end. These are not quarterly or TTM figures. Latest available filed values may include restatements; reporting periods can differ from other providers. Checked: 2026-11-22 05:51 UTC.

MetricUSDBasisPeriod endFiledSource
Revenue$321.33BAnnual2025-09-302025-11-2510-K
Net income$1.55BAnnual2025-09-302025-11-2510-K
Operating cash flow$3.88BAnnual2025-09-302025-11-2510-K
Total assets$76.59BAs of2025-09-302025-11-2510-K
Stockholders’ equity$1.51BAs of2025-09-302025-11-2510-K
Cash and cash equivalents$4.36BAs of2025-09-302025-11-2510-K

✦ Quant Revenue Concentration how this is computed

Single-engine
  • U.S. Healthcare Solutions is the largest reported line at 88.33% of revenue, across 4 reported segments.
  • The next-largest line, International Healthcare Solutions, is a distant second at 9.06% - a sharp slowdown here would have little to offset it.

Revenue annual, last 8 years

Latest year +5.00% YoY

Margins

Gross margin
4.11%
Operating margin
1.41%
Net margin
1.03%

Key ratios & quality

PEG uses trailing P/E against the 3-year net income growth rate (25.91%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG."

Income statement

Line item 2019 2020 2021 2022 2023 2024 2025 2026
Revenue 179.59B189.89B213.99B238.59B262.17B293.96B321.33B337.40B
Gross profit 5.14B5.19B6.94B8.30B8.96B9.91B11.48B13.87B
Selling & admin expenses 2.66B2.77B3.59B4.85B5.31B5.66B6.49B8.08B
Research & development ----------------
Operating profit 2.01B2.03B2.84B2.75B2.69B3.16B3.93B4.74B
Pretax profit 967.11M-5.29B2.22B2.18B2.16B2.00B2.26B4.58B
Tax 112.97M-1.89B677.25M516.52M428.26M484.70M690.52M1.08B
Net profit 854.14M-3.40B1.54B1.67B1.73B1.52B1.57B3.50B
Basic EPS 4-177898818
Diluted EPS 4.04-16.657.398.048.537.537.9617.95

Balance sheet

Line item 2019 2020 2021 2022 2023 2024 2025 2026
Total current assets 28.13B33.06B38.80B39.59B42.80B47.72B52.24B58.45B
Cash & ST investments 3.37B4.60B2.55B3.39B2.59B3.13B4.36B4.88B
Inventory 11.06B12.59B15.37B15.56B17.45B19.00B20.49B21.36B
Total assets 39.17B44.27B57.34B56.56B62.56B67.10B76.59B87.10B
Total current liabilities 29.58B33.85B41.36B43.48B48.83B54.28B57.82B62.38B
Short-term debt 139.01M501.26M300.21M1.07B641.34M576.33M117.79M203.21M
Long-term debt 4.03B3.62B6.38B4.63B4.15B3.81B7.54B11.06B
Total liabilities 36,178,774,000.0045,114,466,000.0056,753,394,000.0056,489,343,000.0061,892,459,000.0066,314,925,000.0074,843,027,000.0083,423,737,000.00
Total equity 2.99B-839.64M584.41M71.27M666.29M786.74M1.75B3.68B
Retained earnings 4.24B518.34M1.67B2.98B4.32B5.42B6.53B--

Cash flow

Line item 2019 2020 2021 2022 2023 2024 2025 2026
Operating cash flow 2.34B2.21B2.67B2.70B3.91B3.48B3.88B4.79B
Depreciation & amortization 497.51M408.01M514.79M709.84M980.85M1.12B1.07B--
Free cash flow 2.03B1.84B2.23B2.21B3.45B3.00B3.21B3.88B
Dividends paid -338.97M-343.58M-366.65M-391.69M-398.75M-416.17M-437.08M-476.81M
Stock buybacks / issuance -674.03M-354.09M-82.15M-483.70M-1.18B-1.49B-435.47M-1.00B
Ending cash balance 3.37B4.60B3.07B3.59B2.75B3.30B4.39B4.97B

Returns & efficiency

Line item 2019 2020 2021 2022 2023 2024 2025 2026
ROE % 29.44-366.53--28,805.771,124.39258.42144.31134.27
ROA % 2.23-8.173.032.982.932.332.164.26
ROIC % 13.92-65.41--30.0035.7231.4824.7432.00
5-year avg ROE % 41.29-29.87------------
EBIT margin % 0.65-2.701.121.010.930.770.831.50
FCF / sales % 1.130.971.040.921.321.021.001.15
Current ratio 0.950.980.940.910.880.880.900.94
Quick ratio 0.530.560.510.510.480.500.510.50
Debt / assets 10.659.3011.6610.087.656.5410.0012.93
LT debt / equity 140.12--2,858.11--794.27590.11500.19300.52
Interest coverage 5.95-32.3913.1710.418.849.066.3810.35
Revenue CAGR (3Y) % 6.947.438.419.9311.3511.1610.438.77
Net income CAGR (3Y) % -15.70---2.4425.70---0.67-2.9225.91
FCF CAGR (3Y) % -9.1720.9827.512.7623.4110.3913.273.97

Revenue breakdown most recent period

Business

U.S. Healthcare Solutions88.33%
International Healthcare Solutions9.06%
Other2.66%

Quote time 2026-11-20 19:52:19 · For reference only, not investment advice and not tailored to your situation.

Cencora discussion 0 comments

Add a comment